Liminal BioSciences Inc. (LMNL)
Company Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.
The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases.
It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage.
The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019.
Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
| Country | CA |
| IPO Date | Dec 18, 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 251 |
| CEO | Bruce Pritchard BA, CA, FIOD |
Contact Details
Address: 440 Armand-Frappier Boulevard Laval, QC CA | |
| Website | https://www.liminalbiosciences.com |
Stock Details
| Ticker Symbol | LMNL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001351172 |
| CUSIP Number | 53272L103 |
| ISIN Number | CA53272L1031 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce Pritchard BA, CA, FIOD | Chief Executive Officer |
| N. Nicole Rusaw C.A., C.P.A. | Chief Financial Officer |
| N. Nicole Rusaw C.A., C.P.A., CA, CPA, HBACC | Chief Financial Officer |
| N. Nicole Rusaw C.A., CPA | Chief Financial Officer |
| Dr. Christopher L. Penney | Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc |
| Dr. Gary J. Bridger Ph.D. | Interim Chief Scientific Officer & Non-Independent Director |
| Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon) | Member of Advisory Committee - Therapeutics |
| Dr. Robert G. Rohwer | Member of Scientific Advisory Committee - PRDT |
| Dr. Steven J. Burton | Pres of Prometic Bioseparations Ltd |
| Marie Iskra L.L.B. | Corporation Sec. & Gen. Counsel |
| Patrick Sartore | Pres |
| Shrinal Inamdar | Mang. of Investor Relations & Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 06, 2023 | 15-12G | Filing |
| Sep 27, 2023 | SC 13D/A | [Amend] Filing |
| Sep 26, 2023 | POS AM | Filing |
| Sep 26, 2023 | 25-NSE | Filing |
| Sep 26, 2023 | POS AM | Filing |
| Sep 26, 2023 | POS AM | Filing |
| Sep 26, 2023 | S-8 POS | Filing |
| Sep 26, 2023 | 6-K | Filing |
| Sep 26, 2023 | SC 13E3/A | [Amend] Filing |
| Sep 26, 2023 | 6-K | Filing |